Lipocine Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 9, 2022. This summary covers the full year, not a standalone fourth quarter.
Business context
Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products for endocrine, metabolic, liver, and CNS disorders. It has no marketed products of its own. Its lead near-term commercial prospect, TLANDO, is licensed exclusively to Antares for U.S. development and commercialization following FDA final approval. Other programs include LPCN 1148 for decompensated cirrhosis, LPCN 1144 for NASH, LPCN 1111 for testosterone replacement, LPCN 1107 for prevention of preterm birth, and neuroactive-steroid candidates.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $16.14 million | $0 |
| Research and development | $7.67 million | $9.75 million |
| General and administrative | $5.33 million | $8.25 million |
| Operating income (loss) | $3.15 million | ($18.00 million) |
| Net income (loss) | ($634,399) | ($20.96 million) |
| Basic and diluted loss per share | ($0.01) | ($0.38) |
| Cash used in operating activities | $4.41 million | $15.30 million |
FY2021 revenue was primarily from the Antares TLANDO license agreement: $11.0 million licensing revenue, $4.05 million minimum guaranteed royalties recognized, approximately $1.04 million for materials, and approximately $55,000 in sales-based royalties. One customer accounted for 99.7% of revenue. The company remains loss-making on a net basis; the year-over-year improvement largely reflects license revenue and a $356,000 noncash gain on warrant liability, compared with a $2.89 million noncash loss in 2020.
At year-end, cash and cash equivalents were $2.95 million and marketable investment securities were $43.69 million, or approximately $46.64 million combined. Current assets were $46.38 million versus current liabilities of $5.62 million. The company reported $2.31 million of current debt; its SVB loan matures June 1, 2022, and includes a $650,000 final payment charge. It also recorded $1.5 million of current and noncurrent liabilities for the Clarus settlement.
Financing activities provided $26.92 million in 2021, principally from the January equity offering and at-the-market share sales, partly offset by $3.33 million of debt repayments. Investing activities used $43.78 million, primarily from net purchases of marketable securities. The company reported 88.29 million common shares outstanding at year-end.
Material changes and notable developments
- Revenue rose from zero in 2020 after the October 2021 Antares TLANDO license agreement; FY2021 results therefore include material, largely non-recurring licensing and related revenue.
- R&D expense declined about 21% and G&A expense about 35% year over year, mainly reflecting lower LPCN 1144/TLANDO development spending and reduced legal and personnel costs.
- Net loss narrowed substantially, but operating cash use continued. The company raised significant equity capital during the year, increasing shares outstanding.
- In July 2021, Lipocine settled all outstanding patent litigation and interference matters with Clarus for $4.0 million: $2.5 million paid immediately, $1.0 million due July 2022, and $500,000 due July 2023. No future royalties are owed between the parties.
- The FDA granted LPCN 1144 Fast Track designation in November 2021. In January 2022, the FDA indicated a 505(b)(2) NDA pathway and accepted the proposed accelerated-approval surrogate endpoint in principle, while recommending dose evaluation and a 72-week Phase 3 study.
Outlook, risks and contingencies
- TLANDO: The FDA had tentatively approved the product but had not granted final approval as of the filing. Antares resubmitted the NDA on January 28, 2022; the FDA classified it as a Class 1 resubmission with a March 28, 2022 target action date. Commercialization and royalties depend on FDA approval and Antares’ execution. Antares is responsible for required post-marketing studies.
- Pipeline timing: Lipocine expected LPCN 1148 Phase 2 enrollment to complete in Q2 or Q3 2022, with 24-week topline results by late 2022 or Q1 2023. The LPCN 1144 open-label extension topline results were expected mid-2022. These are management expectations, not guarantees.
- Liquidity and funding: Management estimated existing resources would fund planned operations through at least March 31, 2023, subject to assumptions. It expects to need additional capital thereafter, or sooner if development spending increases; financing may be unavailable or dilutive. Failure to raise funds could require delays, reductions, or suspension of programs and may threaten continued operations.
- Clinical, regulatory and commercial risks: Most candidates remain investigational; trials may be delayed or fail, FDA requirements may change, and COVID-19 affected LPCN 1148 enrollment. TLANDO faces competition, labeling and safety concerns associated with testosterone therapy, reimbursement uncertainty, and dependence on Antares.
- Legal and governance matters: A shareholder securities class action remained pending; management reported no accrual because loss was not considered probable or estimable. Nasdaq notified the company in January 2022 of noncompliance with board and committee independence requirements, subject to a cure period.
- Controls and audit: Management reported effective disclosure controls and internal control over financial reporting at December 31, 2021. The auditor issued an unqualified opinion on the financial statements and identified warrant valuation and revenue recognition as critical audit matters; it did not audit internal-control effectiveness.
No formal financial guidance for revenue, earnings, or profitability is provided in the supplied filing text.
Most important facts for investors to verify
- Whether TLANDO received final FDA approval on the March 2022 action date, and whether Antares launched it and generated sales or royalties.
- Whether Antares exercised its option to license TLANDO XR by March 31, 2022, and the status of any associated payment or development plan.
- Actual cash runway versus management’s March 31, 2023 estimate, including the effect of the June 2022 SVB maturity and remaining Clarus settlement payments.
- Progress, enrollment and readouts for LPCN 1148 and LPCN 1144, including FDA-agreed trial designs, dose strategy, and Phase 3 funding needs.
- Resolution and potential financial exposure from the shareholder class action, and Nasdaq compliance status.
- Potential dilution from additional financing, outstanding options and warrants, and the company’s limited authorized-share capacity.